Narrative review of GI effects with GLP-1 drugs says cagrilintide-semaglutide data remain limited

This is a narrative expert review of human evidence rather than a new experiment, and it reports no single pooled sample size, so no participant count can be given. The authors state that the review synthesizes evidence from randomized controlled trials, observational studies, meta-analyses, and pharmacovigilance data.

The stated aim was to characterize the incidence, mechanisms, and clinical implications of gastrointestinal adverse effects across approved agents and late-stage pipeline therapies. The background section frames gastrointestinal adverse events as the most common limitation of these therapies and a leading cause of discontinuation.

The authors describe nausea, vomiting, diarrhea, and constipation as established class effects occurring in approximately 30%-50% of patients, typically during initiation and dose escalation. They characterize these events as generally mild to moderate and manageable with dose titration and dietary modification.

Mechanisms listed by the authors include delayed gastric emptying, central activation of emetic pathways, altered intestinal motility, and physiologic effects of rapid weight loss itself. For acute pancreatitis, the review states that randomized trial data are reassuring, with no class-level excess risk demonstrated, while cholelithiasis is described as showing a probable class-level association substantially mediated by weight loss.

On peri-procedural safety, the review reports increased residual gastric volume without confirmed aspiration events.

Cagrilintide, an amylin analogue also described in combination with semaglutide as CagriSema, is mentioned only among late-stage pipeline agents. The review groups cagrilintide-semaglutide with retatrutide and survodutide and states that preliminary data suggest a similar gastrointestinal adverse event profile to approved agents, though evidence remains largely limited.

The abstract reports no doses, schedules, or routes for any agent discussed, including cagrilintide-semaglutide, and presents no new trial results for that combination.

This is a narrative expert review, not a systematic review or meta-analysis, so the abstract describes no search strategy, no inclusion criteria, and no quantitative pooling. Conclusions therefore reflect the authors' synthesis and selection of sources.

The abstract reports no sample size and no dosing regimens. Statements about pipeline agents, including cagrilintide-semaglutide, are explicitly qualified by the authors as preliminary and as resting on evidence that remains largely limited. The pharmacovigilance interpretation for pancreatitis is presented as the most plausible explanation rather than as a demonstrated finding. No funding or conflict-of-interest information appears in the abstract.

Cagrilintide, also known as AM833 or NNC0174-0833 and studied in combination with semaglutide as CagriSema, is not an FDA-approved drug for any use. That status comes from this site's regulatory review, not from the review article summarized here.